Membrane Targets.
Quality of Life.
RudaCure is an AI drug discovery company targeting membrane proteins. The RuCIA platform predicts ion channel and GPCR selectivity to develop therapeutics for dry eye disease (US FDA and Korean Phase 2 IND approved), chronic pain, psoriasis and rare neurological disease. One targeting principle across many indications, 70% faster development, in service of patients' quality of life.
- 4
- Pipeline assets
- Phase 2
- RCI001 clinical stage
- 3
- Therapeutic areas (eye, pain, skin)
- 14
- Partner organisations
Membrane Target Drug Discovery
Our ScienceWe develop membrane-targeted therapeutics using electrophysiology-based ion channel activity measurement. Through patch clamp and high-throughput electrophysiology validation, we discover selective modulators of ion channels such as TRPV1, verifying efficacy and safety of sensory, pain and inflammatory disease treatments with real data.
- Electrophysiology
- Patch Clamp HT Validation
- Membrane Target
- Selective Ion Channel Modulation
- $94B
- Global Chronic Pain by 2030
The Pipeline
Pipeline DetailsTrusted Partners
RCI001 Korea Phase 2 investigational sites
News & Updates
View AllPartner with RudaCure.
We welcome inquiries regarding global licensing, collaborative research, and investment opportunities.